Abstract
Defective apoptosis is a hallmark of the progression of B chronic lymphocytic leukaemia (B-CLL). Smac-mimetics have been shown to induce apoptosis in several tumours. We describe the in vitro pro-apoptotic activity and regulation of the molecular pathway induced by new Smac-mimetics in B-CLL. The cytotoxic effect was significantly higher in B-CLL samples than in healthy controls. No significant synergistic effect was observed in combined treatment. In conclusion one of our compounds (Smac66), used as monotherapy and not in combination, is highly active against B-CLL cells thus suggesting a promising therapeutic potential as a new class of antileukemic drugs in haematology.
Original language | English |
---|---|
Pages (from-to) | 809-815 |
Number of pages | 7 |
Journal | Leukemia Research |
Volume | 37 |
Issue number | 7 |
DOIs | |
Publication status | Published - Jul 2013 |
Keywords
- Apoptosis
- B-CLL
- Caspases
- Smac-mimetics
- Therapy
- TNF
ASJC Scopus subject areas
- Cancer Research
- Hematology
- Oncology